- BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment -
- Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) -
- Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 -
"In 2025, we are focused on clinical execution across our portfolio of next-generation precision therapies for oncology and skeletal dysplasia. We continued to advance TYRA-300 for ACH and intermediate risk non-muscle invasive bladder cancer and will begin dosing in BEACH301 and SURF302 in the second quarter," stated Todd Harris, CEO of TYRA. "In addition, our SURF431 study is now underway, and we dosed the first HCC patient with TYRA-430, our oral FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers."
https://finance.yahoo.com/news/tyra-biosciences-reports-first-quarter-200500962.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.